Oncobiologics Revenue 2015-2021 | OTLK

Oncobiologics revenue from 2015 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Oncobiologics Annual Revenue
(Millions of US $)
2020 $
2019 $8
2018 $3
2017 $4
2016 $3
2015 $5
2014 $9
2013 $9
Oncobiologics Quarterly Revenue
(Millions of US $)
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30 $6
2019-06-30 $1
2019-03-31 $1
2018-12-31 $1
2018-09-30 $1
2018-06-30 $1
2018-03-31 $1
2017-12-31 $1
2017-09-30 $3
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $1
2015-12-31 $1
2015-09-30 $1
2015-06-30 $1
2015-03-31 $0
2014-12-31 $3
2014-09-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.403B $0.008B
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29